Therapeutic phlebotomy is a medical procedure in which a controlled volume of blood is drawn from a vein to treat conditions where the body has too much iron or too many red blood cells. Each session typically removes about 500 mL of blood (roughly one unit), and each unit carries away an estimated 200 to 250 mg of iron.1Dove Press (Journal of Blood Medicine). Clinical applications of therapeutic phlebotomy Though the idea of drawing blood as medicine sounds ancient, and it is, the modern version is grounded in specific diagnoses and measurable targets rather than guesswork.
How Removing Blood Actually Helps
The logic behind therapeutic phlebotomy depends on which problem you are treating, but it boils down to two mechanisms. The first is iron reduction. When blood is removed, the iron locked inside hemoglobin leaves with it. Your body then draws on its stored iron to build replacement red blood cells, gradually depleting the excess. This is the primary mechanism in iron-overload disorders.
The second mechanism is reducing the sheer volume or thickness of the blood. In conditions where the body makes too many red blood cells, the blood becomes viscous, which slows circulation and raises the risk of clots. Removing blood lowers the red cell mass and, with it, viscosity.2Global Journal of Transfusion Medicine. Effect of Therapeutic Phlebotomy on Plasma Volume in Polycythemia Patients In sickle cell disease patients, researchers found that viscosity dropped significantly within just one hour of a session, regardless of the patient’s genetic subtype.3PubMed Central. Therapeutic Phlebotomy Instantly Affects Blood Parameters and Viscosity in Sickle Cell Disease Patients The body also begins compensating almost immediately: fluid shifts from surrounding tissue into the bloodstream within minutes, replacing a portion of the lost volume within the first hour.4PubMed. Fluid Shifts After Hemorrhage That rapid refill is why most people can walk out of a session feeling relatively normal.
Hereditary Hemochromatosis
The most common reason people undergo therapeutic phlebotomy is hereditary hemochromatosis, a genetic condition in which the body absorbs too much dietary iron. Without treatment, iron accumulates in the liver, heart, pancreas, and joints, eventually causing organ damage. Phlebotomy is considered the gold standard for this condition because it is simple, effective, and has been used for decades.
Treatment typically happens in two phases. During the induction phase, you have blood drawn regularly, often weekly or every two weeks, until your ferritin level drops below a target. European guidelines set that induction target at ferritin below 50 micrograms per liter, with a maintenance target below 100.5PubMed. EASL Clinical Practice Guidelines on haemochromatosis Once you reach maintenance, the frequency drops to every few months, enough to keep iron from building back up. For people with smaller body size, anemia, or heart or lung conditions, a half unit (about 250 mL) may be removed per session instead of the standard full unit.1Dove Press (Journal of Blood Medicine). Clinical applications of therapeutic phlebotomy
The induction phase can be a significant commitment. Some patients need dozens of sessions over many months before their iron stores normalize. But the treatment genuinely works: getting iron levels down prevents or halts liver fibrosis, and in people diagnosed before organ damage sets in, life expectancy can be completely normal.
Polycythemia Vera
Polycythemia vera is a blood cancer in which the bone marrow overproduces red blood cells. The resulting increase in blood thickness raises the risk of strokes, heart attacks, and blood clots. For every patient with this condition, phlebotomy is the first-line treatment. The target is to keep hematocrit, the percentage of blood volume occupied by red cells, below 45%.6PubMed. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
Unlike hemochromatosis, where the goal is eventually to reach maintenance and slow down, polycythemia vera often requires lifelong management. The bone marrow does not stop overproducing, so the phlebotomies keep coming. Some patients also take low-dose aspirin daily and, if their risk profile warrants it, additional medications to suppress red cell production. But even when drugs are added, phlebotomy usually remains part of the picture. One clinical protocol used sessions of 350 mL every three days until hematocrit came under control.7PubMed. Revisiting the impact of serial therapeutic phlebotomy in polycythaemia on laboratory and clinical parameters using a fixed interval and fixed volume protocol
Other Established Uses
Beyond hemochromatosis and polycythemia vera, phlebotomy is an accepted treatment for a handful of other conditions. Porphyria cutanea tarda is a disorder in which iron buildup disrupts the production of heme, the molecule that carries oxygen in red blood cells. The result is painful skin blistering, especially on sun-exposed areas. Phlebotomy is consistently effective at resolving symptoms, and the mechanism appears to be the same iron-reduction pathway at work in hemochromatosis.8PubMed. Phlebotomy treatment of porphyria cutanea tarda
Sickle cell disease is another established indication, though the goal there is different. In sickle cell patients, the aim is to reduce the proportion of abnormal hemoglobin and lower blood viscosity, which can reduce the frequency and severity of pain crises. Research has shown that the ratio between hematocrit and viscosity, a proxy for how effectively red cells can deliver oxygen, improved after phlebotomy in certain sickle cell genotypes.3PubMed Central. Therapeutic Phlebotomy Instantly Affects Blood Parameters and Viscosity in Sickle Cell Disease Patients
The Debate Over Fatty Liver Disease
Nonalcoholic fatty liver disease with elevated ferritin is one of the more contested indications. The theory is straightforward: many people with fatty liver have higher-than-normal iron levels, and excess iron can worsen liver inflammation. If phlebotomy lowers iron, it might slow the disease.
The evidence here is genuinely mixed. A systematic review and meta-analysis found that phlebotomy significantly lowered insulin resistance, reduced a key liver enzyme (ALT), lowered triglycerides, and raised “good” cholesterol (HDL) compared to controls.9PubMed Central. Outcome of Phlebotomy for Treating Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis A separate trial found that phlebotomy improved liver enzymes and liver tissue appearance significantly over six months.10PubMed Central. Effects of Phlebotomy on Liver Enzymes and Histology of Patients with Nonalcoholic Fatty Liver Disease
But a rigorous randomized controlled trial reached the opposite conclusion. At six months, there was no difference between phlebotomy and control groups in liver fat, liver enzymes, or insulin resistance, even when the analysis was restricted to patients who started with elevated ferritin.11PubMed. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial The disagreement likely reflects differences in study design, patient selection, and how outcomes were measured. For now, phlebotomy for fatty liver disease remains in a gray area, sometimes used but without the confident evidence base that supports its role in hemochromatosis or polycythemia vera.
What a Session Looks Like
If you have never had a therapeutic phlebotomy, the experience is similar to donating blood, but with more clinical oversight. You sit or recline in a chair. A nurse or phlebotomist cleans a site on the inside of your elbow, inserts a needle into a vein, and collects the prescribed amount of blood into a bag. The standard volume is about 450 to 500 mL, though the amount may be reduced for patients who are small, elderly, or have cardiac or lung conditions. A session usually takes 15 to 30 minutes for the draw itself, plus time afterward for monitoring.
You are generally advised to drink extra fluids before and after, eat a meal beforehand, and avoid strenuous activity for the rest of the day. The fluid your body pulls into the bloodstream from surrounding tissue replaces a significant chunk of the lost volume within the first hour, though full red blood cell recovery takes weeks.4PubMed. Fluid Shifts After Hemorrhage During the induction phase for hemochromatosis, sessions can occur as often as weekly, which means your hemoglobin may not fully bounce back between sessions. Doctors monitor this to make sure you do not become significantly anemic.
Risks and Side Effects
Therapeutic phlebotomy is one of the safer medical procedures around, but “safe” does not mean side-effect-free. A prospective study of 587 procedures found that about 4% of sessions produced an adverse event, most commonly vasovagal reactions: lightheadedness, nausea, or briefly fainting. None of the events were clinically serious, and all were managed on-site by nursing staff.12PubMed. Adverse effects of therapeutic phlebotomies: Prospective study of 587 procedures
That said, the experience of living with repeated phlebotomies over months or years is different from the experience of a single session. A survey of hemochromatosis patients found that while roughly 87% considered treatment “quite worthwhile” or “very worthwhile,” over half of patients in the intensive induction phase reported side effects “always” or “most of the time.” About 16% said they would probably or definitely decline phlebotomy if other options were available.13PubMed. Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment Common complaints include fatigue, bruising at the needle site, and feeling drained for a day or two afterward. The cumulative effect of iron depletion can also lead to symptoms of low iron, such as restless legs, cold intolerance, and difficulty concentrating, even before ferritin falls below the treatment target.
Alternatives When Phlebotomy Is Not Feasible
Phlebotomy works well for most people with iron overload, but it is not practical for everyone. Patients who are significantly anemic, for example, cannot afford to lose more red blood cells. People with iron overload caused by conditions that require frequent blood transfusions, like thalassemia major, are in a bind: they accumulate iron from the transfusions, but their underlying anemia makes phlebotomy dangerous. For these patients, iron chelation therapy, medications that bind iron so the body can excrete it, is the primary alternative.14Pharmacotherapy. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy
Another alternative is erythrocytapheresis, a procedure that selectively removes red blood cells while returning the plasma and other blood components back to you. In a randomized crossover trial comparing the two approaches in hemochromatosis patients on maintenance therapy, erythrocytapheresis required significantly fewer sessions per year than standard phlebotomy (about 1.9 versus 3.3), and the time between treatments was more than twice as long.15PubMed. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial That sounds appealing, but there are trade-offs. A separate study found that while erythrocytapheresis did produce a faster initial drop in ferritin, the time to actually reaching the target ferritin level was the same as with regular phlebotomy. Material costs were about three times higher with apheresis, and technician time trended higher as well.16PubMed Central. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis For most hemochromatosis patients, standard phlebotomy remains the practical first choice.
The Testosterone Therapy Complication
A growing population of people encountering phlebotomy for the first time are men on testosterone replacement therapy. Testosterone stimulates red blood cell production, and a common side effect of treatment is erythrocytosis, an elevated red cell count that can push hematocrit above safe thresholds. Many clinical guidelines recommend phlebotomy to bring hematocrit down if it climbs too high.
This recommendation, however, rests on surprisingly thin ground. A recent review pointed out that there is essentially no evidence showing that phlebotomy is either effective or safe for lowering hematocrit in testosterone-induced erythrocytosis specifically. The concern is that repeated phlebotomy depletes iron stores and lowers the oxygen-carrying capacity of the blood, which can trigger biological pathways that may paradoxically increase clotting risk.17PubMed Central. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? This does not mean the practice is harmful, but it highlights a gap between what guidelines recommend and what the evidence firmly supports. If you are on testosterone and have been told you need phlebotomy, it is worth having a detailed conversation with your prescribing physician about the rationale and monitoring plan.
Tracking Progress During Treatment
The standard way doctors monitor phlebotomy treatment is through regular blood tests, primarily ferritin and transferrin saturation for iron-overload conditions, and hematocrit for polycythemia vera. But ferritin is not always a perfect marker. It can be elevated by inflammation, infection, or liver disease independently of iron stores, which makes it harder to interpret in patients who have more than one thing going on.
One alternative biomarker that has shown promise is soluble transferrin receptor, or sTfR. In hemochromatosis patients undergoing phlebotomy, sTfR levels rise as iron stores are depleted, potentially signaling that iron is running low before the patient actually becomes anemic. Researchers have suggested sTfR could serve as an early warning to adjust treatment frequency before side effects appear.18PubMed. Soluble transferrin receptor in hemochromatosis patients during phlebotomy therapy This is not yet routine practice everywhere, but it represents the kind of refinement that can make a centuries-old treatment more precise.
Can Phlebotomy Blood Be Used for Transfusions?
One question that comes up frequently among hemochromatosis patients is whether the blood removed during treatment could help someone else. The answer, frustratingly, depends on where you live. In many countries, including parts of the United States, blood banks have historically refused blood collected during therapeutic phlebotomy from hemochromatosis patients. The reasoning involves two theoretical concerns: that iron-overloaded blood might carry a higher risk of certain infections (particularly from bacteria that thrive in iron-rich environments), and that donors who are undergoing treatment rather than volunteering freely might be less forthcoming about risk factors.
Neither concern has held up under scrutiny. A comprehensive review found no convincing evidence that blood from hemochromatosis patients poses additional infectious risk, and concluded that these patients should be allowed into the donor pool.19PubMed. Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis A prospective study at centers that did accept hemochromatosis donors found that they safely and meaningfully increased the blood supply, and that integrating phlebotomy therapy with donation removed financial barriers to care and reduced incentives for patients to hide health information.20PubMed. Hemochromatosis subjects as allogeneic blood donors: a prospective study Policies are slowly shifting, but the inconsistency remains a source of frustration for patients who would prefer their blood go to good use.
From Bloodletting to Evidence-Based Practice
It is hard to discuss therapeutic phlebotomy without acknowledging its ancestor: bloodletting. For thousands of years, physicians drained blood to treat virtually every ailment imaginable, from fevers to mental illness, based on the humoral theory that disease arose from imbalances in bodily fluids. The practice caused enormous harm and persisted largely because the medical establishment resisted challenges to tradition.21PubMed. History of bloodletting by phlebotomy
Modern therapeutic phlebotomy shares the basic mechanics but almost nothing else. Today, blood is removed only when measurable lab values indicate a specific excess, and treatment targets are defined by clinical guidelines, not philosophy. The transformation from indiscriminate bloodletting to evidence-based phlebotomy happened primarily from the nineteenth century onward, and it happened against resistance. Knowing that history is a useful reminder: the value of any medical treatment comes from the evidence behind it, not from how long people have been doing it. Therapeutic phlebotomy earns its place in modern medicine because we can measure what it does and confirm that the benefits outweigh the costs for the conditions where it is indicated.
Rare and Emerging Applications
Beyond the well-established indications, phlebotomy occasionally appears in case reports for unusual situations. One example involves children with complex congenital heart disease who develop a condition called cyanotic nephropathy, where chronically low oxygen levels and high red blood cell counts damage the kidneys. In a reported case, a 12-year-old boy with inoperable heart disease and worsening kidney function underwent phlebotomy after standard medications failed. His kidney function improved and he became less cyanotic, though the benefits were temporary and required repeated sessions.22Journal of Renal Injury Prevention. Phlebotomy improves kidney function in pediatric cyanotic nephropathy: A case report A single case report does not establish a treatment, but it illustrates how the basic principle of reducing blood viscosity and red cell mass can be applied creatively when other options are exhausted. There are no standardized pediatric protocols for therapeutic phlebotomy in these settings, and the field is largely guided by individual clinical judgment and very small studies.